spacer
home > pmps > spring 2007 > the other drug problem
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

The Other Drug Problem

Hot in the pursuit of adequate advances in medication regimens, Tassilo Korab argues packaging design can contribute to patient compliance

Patient compliance with medicinal therapy is an issue of increasing concern to public health, costing the health insurance industry and the taxpayer enormous sums of money, and putting at risk many patients’ lives. Investigations show that approximately one third of patients take their medicine as prescribed, one third take some as prescribed and one third do not take any at all. Noncompliance leads to 10 per cent of hospital admissions and 23 per cent of nursing home admissions. The various investigations into the subject estimate the costs directly linked to non-compliance to be in excess of US$100 billion annually in the US alone.

Packaging has an undeniable influence on compliance and the safe application of medicines. The various functions of packaging will always have to find a compromise between numerous objectives and conflicting interests. Drug packaging can either build barriers between the patient and the medicine, or can enhance compliance by incorporating features and functions that help patients follow the therapy plan.

Medicinal therapy can only be beneficial if the patients adhere to the regimen. This applies in particular to modern drugs which, according to the ever increasing efficacy of the active substances and the consequently reduced contents of those in the tablets, require a higher level of compliance.

KEEPING COMPLIANT

Patient compliance is an issue as old as medicinal therapy itself. Hippocrates warned: “To keep watch for that fault in patients which makes them lie about the things prescribed.” Today, patient compliance has become the best documented, but least understood health related behaviour. In 1989, the US National Council on Patient Information and Education (NCPIE) coined the phrase ‘America’s Other Drug Problem’ and since then, other organisations have adopted this phrase when referring to medicine misuse.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Starting his career as an International Sales Manager, Tassilo Korab has been in the packaging industry for more than 20 years. He has concentrated on patient compliance, standards and regulations for child resistant packaging and the war against counterfeits. As a recognised expert in flexible packaging, he holds a MSc in Healthcare Management, as well as having written several publications. Tassilo is Managing Director of TKM HandelsgmbH, Vienna, Austria, a consulting company in the sector of Flexible Packaging for the pharmaceutical and healthcare industries. He was one of the co-founders of HCPC Europe, the Healthcare Compliance Packaging Council. He has been representing the organisation first as funding member and member of the board and, since September 2005, as Executive Director.
spacer
Tassilo Korab
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Destiny Pharma appoints MedPharm to develop new XF-platform drug formulations

Destiny Pharma, a clinical stage biotechnology company focused on the development of novel antimicrobial drugs, is pleased to announce that it has appointed MedPharm as its expert partner to develop new topical formulations of the Company’s novel XF-platform compounds. These new treatments for dermal and ocular infections are part of its second clinical programme to address the global problem of anti-microbial resistance (AMR). MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de-risk development programmes.
More info >>

White Papers

Crunch Time: The Impact of Serialisation Requirements on Packaging Operations

PCI Pharma Services

The deadlines for including unique product identifiers on prescription drugs is putting a strain on multiple parts of the industry, much of which is ill-prepared to meet the target. Here, we look to the experience of a company that is ahead of the curve for lessons on how to manage and ease the transition to serialisation.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement